跳至主要内容
临床试验/JPRN-UMIN000003354
JPRN-UMIN000003354已完成2 期

A phase II study of carboplatin plus pemetrexed followed by gefitinib for stage IIIB/IV non-small cell lung cancer with EGFR mutation - carboplatin, pemetrexed and gefitinib for lung cancer with EGFR mutation

Kanagawa Cancer Center0 个研究点目标入组 60 人开始时间: 2010年3月23日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 75years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients who had received chemotherapy or radiotherapy were excluded. Patients who have massive pleural effusion or pericardial effusion, who have uncontrolled cardiac disease, diabetes mellitus or hypertension, who have infectious disease, who have interstitial pneumonitis, were excluded.

研究者

相似试验